Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09JKS
|
|||
| Former ID |
DIB014625
|
|||
| Drug Name |
GRASPA
|
|||
| Synonyms |
L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech
Click to Show/Hide
|
|||
| Drug Type |
Protein
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C91.0] | Phase 3 | [1] | |
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 1 | [2] | ||
| Company |
Erytech Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Asparaginase (ASRGL1) | Target Info | Modulator | [3] |
| BioCyc | Asparagine degradation | |||
| Pathwhiz Pathway | Aspartate Metabolism | |||
| Ammonia Recycling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01518517) GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia (GRASPIVOTALL). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01523808) Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 3 | l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011 Apr;153(1):58-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.